Condensed Consolidated Statements of Operations (Unaudited) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Revenues:
Product sales	$ 1,464	$ 1,945	$ 4,835	$ 5,030
Research and development income	496	119	1,368	539
Licensing, royalty and other income	26	49	52	142
Total revenues	1,986	2,113	6,255	5,711
Cost and expenses:
Cost of sales	1,222	1,479	4,271	4,113
Selling, general and administrative expenses	980	609	2,254	2,300
Product development and research expenses	620	442	1,735	1,573
Total costs and expenses	2,822	2,530	8,260	7,986
Operating loss	(836)	(417)	(2,005)	(2,275)
Interest expense and other, net	(586)	(70)	(740)	(193)
Net loss	$ (1,422)	$ (487)	$ (2,745)	$ (2,468)
Basic and diluted loss per share (in Dollars per share)	$ (0.04)	$ (0.01)	$ (0.07)	$ (0.06)
Weighted Average of Common Stock and Common Stock Equivalents Outstanding
Basic and diluted (in Shares)	39,508,217	39,498,096	39,510,540	39,432,061